Eric has a strong multidisciplinary background in metabolic disease and oncology targets with over 20 years of experience in the biotech/pharmaceutical industry. Prior to joining RayzeBio, he served as Vice President Development & Operations at Metacrine, Inc. a mid-stage clinical development company where he oversaw nonclinical development of the lead clinical assets for non-alcoholic steatohepatitis (NASH). Prior to Metacrine, he served as Senior Director of Operations at Seragon Pharmaceuticals and was involved in business development efforts resulting in the $1.7B acquisition of Seragon by Genentech, for an upfront payment of $725M and $1B in contingent development milestones. Prior to Ser agon, he served as Director of Operations at Aragon Pharmaceuticals on the development of apalutamide which was successfully commercialized following Aragon’s acquisition by Johnson & Johnson for $1B. In previous positions, Eric worked as a pharmacologist with numerous scientific publications on oncology and metabolic disease targets at companies including X-Ceptor Therapeutics, acquired by Exelixis, Ligand Pharmaceuticals and Hybritech, Inc. Eric is a graduate of the University of California at San Diego.

Arvind has over 13 years of investment banking experience. Before joining RayzeBio, he was a Managing Director in the healthcare investment banking team at Bank of America Securities, advising biopharmaceutical companies on strategic and financing transactions. During his 13 years at Bank of America Securities, he executed over $100 billion in M&A transactions and over $12 billion in equity and equity-linked financings. Prior to joining Bank of America Securities, he was an engineer at Caritor India Pvt. Ltd.

Arvind holds a Bachelor in Engineering in Computer Science from Visvesvaraya Technological University and an MBA from Goizueta Business School, Emory University.

Susan has over 20 years of combined industry and academic experience, successfully leading programs through IND clearance to full regulatory approval. Susan has led development, registration, and post-marketing support of products for bile duct, urothelial, gastric, breast, prostate, and thyroid cancer and pediatric low-grade glioma. Before joining RayzeBio, she was Chief Medical Officer at QED Therapeutics, an affiliate of BridgeBio Pharma, where she oversaw the clinical development of infigratinib for oncology and skeletal dysplasia indications, leading to the approval of Truseltiq. Prior to QED, Susan was VP and Head of Clinical Development for Puma Biotechnology, contributing to the approval of Nerlynx. Before Puma, she held senior positions at Millennium and Genzyme. Susan also serves on the board of directors of BioAtla. 

Susan is a board-certified internist and previously held faculty appointments at the University of Pennsylvania School of Medicine and Harvard Medical School. Susan received her BA from the University of Virginia, MD from Duke University, and MS in Clinical Epidemiology from the University of Pennsylvania School of Medicine.